CD244 overexpression indicates NK cell dysfunction and tumor progression in diffuse large B-cell lymphoma - Report - MDSpire

CD244 overexpression indicates NK cell dysfunction and tumor progression in diffuse large B-cell lymphoma

  • By

  • Yiming Yang

  • Biyang Zeng

  • Huimin Yang

  • Xin Liu

  • Peilin Li

  • Chao Mai

  • Shunhai Jian

  • Qiqi Zhu

  • July 7, 2026

  • 0 min

Share

Clinical Report: Elevated CD244 Levels Correlate with NK Cell Impairment in DLBCL

Overview

This study investigates the role of CD244 in diffuse large B-cell lymphoma (DLBCL), highlighting its correlation with natural killer (NK) cell dysfunction.

Background

Diffuse large B-cell lymphoma (DLBCL) accounts for approximately 40% of non-Hodgkin lymphoma cases and presents significant heterogeneity in clinical features and treatment responses. The tumor microenvironment (TME) plays a role in DLBCL progression and therapeutic resistance.

Data Highlights

No numerical data provided in the source material.

Key Findings

  • NK cells are the primary CD244-expressing population in DLBCL.
  • Elevated CD244 expression correlates with an immunosuppressive TME.
  • CD244 expression is associated with clinicopathological features.
  • EAT2 is identified as the predominant intracellular adaptor for CD244.
  • CD244 expression may be regulated by STAT3 activation in NK cells.

Clinical Implications

Understanding the regulatory mechanisms of CD244 could inform future immunotherapy strategies.

Conclusion

This study highlights the role of CD244 in NK cell dysfunction and DLBCL progression.

Related Resources & Content

  1. Blood Cancer Journal, Current treatment algorithm: diffuse large B cell lymphoma, 2026 -- Current treatment algorithm: diffuse large B cell lymphoma
  2. Blood Cancer Journal, Reduced peripheral blood natural killer (NK) cell levels negatively impact the prognosis of follicular lymphoma patients, 2016 -- Reduced peripheral blood natural killer (NK) cell levels negatively impact the prognosis of follicular lymphoma patients
  3. Blood Cancer Journal, High prevalence of oncogenic MYD88 and CD79B mutations in diffuse large B-cell lymphomas presenting at immune-privileged sites, 2013 -- High prevalence of oncogenic MYD88 and CD79B mutations in diffuse large B-cell lymphomas presenting at immune-privileged sites
  4. Blood Cancer Journal, Prognostic and Therapeutic Insights from the Molecular Diversity of CD30+ Diffuse Large B-Cell Lymphoma, 2022 -- Prognostic and Therapeutic Insights from the Molecular Diversity of CD30+ Diffuse Large B-Cell Lymphoma
  5. Blood Cancer Journal — CDK9 as a Critical Factor in GATA-3 Driven T-cell Lymphomas Independent of MCL-1
  6. Current treatment algorithm: diffuse large B cell lymphoma | Blood Cancer Journal
  7. Genetic mechanisms underlying tumor microenvironment composition and function in diffuse large B-cell lymphoma - ScienceDirect

Original Source(s)

CD244 overexpression indicates NK cell dysfunction and tumor progression in diffuse large B-cell lymphoma

  • by Yiming Yang, Biyang Zeng, Huimin Yang, Xin Liu, Peilin Li, Chao Mai, Shunhai Jian, Qiqi Zhu

  • July 7, 2026

Related Content

Coexpression of GITRL confers resistance to Treg cell-mediated immunosuppression to anti-CD19 CAR-NK cells

Bridging the gap in pediatric cancer rehabilitation care: a multi-perspective survey study

Single-port robotic segmentectomy using the da Vinci SP system for non-small cell lung cancer